Molecular mechanisms of chemo‐and radiotherapy resistance and the potential implications for cancer treatment
YP Liu, CC Zheng, YN Huang, ML He, WW Xu… - MedComm, 2021 - Wiley Online Library
Cancer is a leading cause of death worldwide. Surgery is the primary treatment approach for
cancer, but the survival rate is very low due to the rapid progression of the disease and …
cancer, but the survival rate is very low due to the rapid progression of the disease and …
(Nano) platforms in bladder cancer therapy: Challenges and opportunities
M Ashrafizadeh, A Zarrabi… - Bioengineering & …, 2023 - Wiley Online Library
Urological cancers are among the most common malignancies around the world. In
particular, bladder cancer severely threatens human health due to its aggressive and …
particular, bladder cancer severely threatens human health due to its aggressive and …
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Z Shi, L Hao, X Han, ZX Wu, K Pang, Y Dong, J Qin… - Molecular Cancer, 2022 - Springer
Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial
carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic …
carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic …
Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11
RM Drayton, E Dudziec, S Peter, S Bertz… - Clinical cancer …, 2014 - AACR
Purpose: Resistance to cisplatin-based chemotherapy is a major obstacle to bladder cancer
treatment. We aimed to identify microRNAs (miRNA) that are dysregulated in cisplatin …
treatment. We aimed to identify microRNAs (miRNA) that are dysregulated in cisplatin …
Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation
Cisplatin-based chemotherapeutic regimens are the most frequently used (neo) adjuvant
treatments for the majority of solid tumors. While platinum-based chemotherapeutic …
treatments for the majority of solid tumors. While platinum-based chemotherapeutic …
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin
The tumor microenvironment (TME) serves as a multidrug resistant center for tumors under
the assault of chemotherapy and a physiological barrier against the penetration of …
the assault of chemotherapy and a physiological barrier against the penetration of …
Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy
Encapsulation of cisplatin (CDDP) into nanoparticles (NPs) with high drug loading and
encapsulation efficiency has been difficult due to the poor solubility of CDDP. However, this …
encapsulation efficiency has been difficult due to the poor solubility of CDDP. However, this …
Glucose metabolism reprogramming in bladder cancer: hexokinase 2 (HK2) as prognostic biomarker and target for bladder cancer therapy
Simple Summary Urothelial bladder carcinoma entails significant health costs due to the
high recurrence rates and poor response to standard cisplatin-based treatment. The …
high recurrence rates and poor response to standard cisplatin-based treatment. The …
Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin
X Wang, F Zhang, XR Wu - Scientific reports, 2017 - nature.com
Chemoresistance to cisplatin is a principal cause of treatment failure and mortality of
advanced bladder cancer (BC). The underlying mechanisms remain unclear, which hinders …
advanced bladder cancer (BC). The underlying mechanisms remain unclear, which hinders …
Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer
Heterogeneous nuclear ribonucleoprotein K (hn RNPK) is an essential RNA‐and DNA‐
binding protein that regulates diverse biological events, especially DNA transcription. hn …
binding protein that regulates diverse biological events, especially DNA transcription. hn …